ASYMCHEM LABORATORIES (TIANJIN) CO., LTD.

Asymchem Laboratories (Tianjin) Co., Ltd.

002821

CNE100002BZ6

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 27/06/2024 BST			5-day change	1st Jan Change
65.8 ^CNY	-2.52%		-8.16%	-43.32%

06-26	Asymchem Appoints Cheng Yi Chen as CTO of Small-Molecule Sector	CI
06-24	Asymchem Laboratories Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 28 June 2024	CI

Asymchem Laboratories Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 28 June 2024

June 24, 2024 at 08:32 pm

Asymchem Laboratories (Tianjin) Co., Ltd. announced final cash dividend/10 shares (tax included) of CNY 18.00000000 on A shares for the year 2023. Record date: 27 June 2024. Ex-date: 28 June 2024.

Payment date: 28 June 2024.

Latest news about Asymchem Laboratories (Tianjin) Co., Ltd.

Asymchem Appoints Cheng Yi Chen as CTO of Small-Molecule Sector	06-26	CI
Asymchem Laboratories Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 28 June 2024	06-24	CI
Asymchem Laboratories Co., Ltd. Approves Final Ordinary Dividend for the Year Ended 31 December 2023, Payable on 12 July 2024	06-06	CI
Asymchem Appoints Franck Mevellec as Senior Director, Business Development	05-29	CI
Asymchem Laboratories Buys Pfizer's Former UK Site; Hong Kong Shares Slide 3%	05-23	MT
China-Based Asymchem Laboratories Will Operate Former Pfizer Manufacturing Facility in UK	05-21	DJ
Asymchem Laboratories Co., Ltd. Secures Former Pfizer Sandwich, UK, Development and API Pilot Plant Manufacturing Facilities	05-21	CI
Asymchem Laboratories' Profit Drops 55%, Operating Income Slumps 38% in Q1; Shares Up 3%	04-29	MT
Nomura Adjusts Asymchem Laboratories’ Price Target to HK$83.94 From HK$90.12 Keeps at Buy	04-26	MT
Nomura Adjusts Asymchem Laboratories’ Price Target to 118.48 Yuan From 127.21 Yuan Keeps at Buy	04-26	MT
Asymchem Laboratories Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-25	CI
Tranche Update on Asymchem Laboratories Co., Ltd.'s Equity Buyback Plan announced on March 8, 2024.	04-02	CI
Asymchem Laboratories' Profit Falls 31% as Revenue Drops 24% in 2023	03-29	MT
Asymchem Laboratories Co., Ltd. Proposes Final Ordinary Dividend for the Year Ended 31 December 2023	03-28	CI
Asymchem Laboratories Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Asymchem Laboratories Completes A-Share Repurchase Program	03-27	MT
Asymchem Laboratories Co., Ltd. commences an Equity Buyback Plan for CNY 1,200 million worth of its shares, under the authorization approved on February 29,2024.	03-07	CI
Nomura Adjusts Asymchem Laboratories Tianjin’s Price Target to HK$90.12 From HK$134.59, Keeps at Buy	03-04	MT
Nomura Adjusts Asymchem Laboratories (Tianjin)’s Price Target to 127.21 Yuan From 189.98 Yuan, Keeps at Buy	03-04	MT
Asymchem Laboratories Co., Ltd. Appoints Hou Xinyi as an Independent Non-Executive Director, Effective 29 February 2024	02-29	CI
Asymchem Laboratories Co., Ltd. Announces Resignation of Wang Qingsong as Independent Non-Executive Director and Committees	02-05	CI
Asymchem's Shenzhen Shares Jump 7% on 1.2 Billion Yuan Stock Buyback	02-01	MT
INSTANT VIEW 8-China Evergrande ordered to liquidate by Hong Kong court	01-29	RE
Chinese Shares Retreat to Four-Year Lows Ahead of Trade, Inflation Data; Bolong Equipment Surges 17% in Shanghai Debut	01-10	MT
China's policy dilemma: is boosting credit deflationary?	01-10	RE

Chart Asymchem Laboratories (Tianjin) Co., Ltd.

Duration

Period

Chart Asymchem Laboratories (Tianjin) Co., Ltd.

More charts

Asymchem Laboratories Tianjin Co Ltd is a China-based company mainly engaged in providing one-stop comprehensive services for pharmaceutical outsourcing. The Company's business includes customized research and development and production of small molecule drugs (CDMO), chemical macromolecule CDMO, clinical research services, formulation CDMO, biological macromolecule CDMO, technology output and synthetic biology. The Company's product categories cover peptides, oligonucleotides, monoclonal antibodies, antibody-conjugated drugs and messenger RNA. The Company mainly conducts its business in domestic and foreign markets.

Sector

Pharmaceuticals

Calendar

14/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Asymchem Laboratories (Tianjin) Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

65.8 CNY

Average target price

99.42 CNY

Spread / Average Target

+51.10%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASYMCHEM LABORATORIES (TIANJIN) CO., LTD.	-43.32%	3.18B
ELI LILLY AND COMPANY	+55.32%	819B
JOHNSON & JOHNSON	-6.75%	351B
MERCK & CO., INC.	+13.56%	329B
ABBVIE INC.	+10.68%	298B
ASTRAZENECA PLC	+16.57%	242B
ROCHE HOLDING AG	+2.04%	225B
NOVARTIS AG	+13.31%	217B
AMGEN INC.	+8.48%	168B
PFIZER, INC.	-2.81%	158B

Other Pharmaceuticals

Asymchem Laboratories (Tianjin) Co., Ltd.

Equities

002821

CNE100002BZ6

Pharmaceuticals

Asymchem Laboratories Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 28 June 2024

Latest news about Asymchem Laboratories (Tianjin) Co., Ltd.

Chart Asymchem Laboratories (Tianjin) Co., Ltd.

Company Profile

Income Statement Evolution

Ratings for Asymchem Laboratories (Tianjin) Co., Ltd.

Analysts' Consensus

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Other Pharmaceuticals